Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants >or=35 weeks gestation.
about
Effects of Hyperbilirubinemia on Auditory Brainstem Response of Neonates Treated with Phototherapy.Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.Individualized follow up programme and early discharge in term neonates.Measurements of neonatal bilirubin and albumin concentrations: a need for improvement and quality control.Riluzole is a promising pharmacological inhibitor of bilirubin-induced excitotoxicity in the ventral cochlear nucleus.The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation.Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-κB leads to hyperbilirubinemia.Risk factors for acute bilirubin encephalopathy on admission to two Myanmar national paediatric hospitalsBiliCheck vs JM-103 in identifying neonates not at risk of hyperbilirubinaemiaUniversal bilirubin screening for severe neonatal hyperbilirubinemia.The side effects of phototherapy for neonatal jaundice: what do we know? What should we do?Severe neonatal jaundice: is it a rare event in Australia?Perinatal outcome of singleton versus twin late preterm infants: do twins mature faster than singletons?Cadmium and arsenic override NF-κB developmental regulation of the intestinal UGT1A1 gene and control of hyperbilirubinemia.Kernicterus in the 21st century: frequently asked questions.Service readiness for inpatient care of small and sick newborns: what do we need and what can we measure now?
P2860
Q30391080-B518367B-3C99-4A76-9B22-66C7EC9B366AQ30445380-51ADB82A-E9A5-45E0-BB32-FE7148D5E30BQ34468498-2B732582-269F-4D28-9A0A-BE156E518F84Q35113464-6EF7C7EE-E58E-4CEE-9F96-8854C89F3803Q35509970-8EBED28D-104F-4D34-8B6C-F2E0A71FF1A9Q35992575-7B692650-7923-44F7-8173-D9BE296DA9EFQ36191283-15327564-8A0C-4DB9-87C4-A80D73860B67Q36774032-5946121E-5D22-4484-BA79-559B9757A566Q37071640-17DE6C75-2368-49D1-806D-5B91271730DDQ37793851-D66C70DE-190E-49AC-ACBB-6DEB1D317738Q37860225-0213EE6E-6387-4716-8402-6074E9AB8B8DQ37955211-E8BC2A39-D058-4CD7-8913-E0E4DAF2C34DQ38535590-A3CC66C4-4BE8-4C1E-9C22-4335578755E2Q41009174-F9852521-5286-4AE0-AFA9-F8E9FF0C427CQ48747681-098C069E-F8DA-4D29-8502-52E3152720A0Q58045909-13997CC2-C8D3-4754-96A0-ECA09F6C08FD
P2860
Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants >or=35 weeks gestation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of jaundice and pre ...... nfants >or=35 weeks gestation.
@en
Management of jaundice and pre ...... nfants >or=35 weeks gestation.
@nl
type
label
Management of jaundice and pre ...... nfants >or=35 weeks gestation.
@en
Management of jaundice and pre ...... nfants >or=35 weeks gestation.
@nl
prefLabel
Management of jaundice and pre ...... nfants >or=35 weeks gestation.
@en
Management of jaundice and pre ...... nfants >or=35 weeks gestation.
@nl
P2093
P2860
P356
P1433
P1476
Management of jaundice and pre ...... nfants >or=35 weeks gestation.
@en
P2093
Ann R Stark
European Society for Pediatric Research
Expert Committee for Severe Neonatal Hyperbilirubinemia
Giuseppe Buonocore
M Jeffrey Maisels
Vinod K Bhutani
P2860
P356
10.1159/000113463
P407
P577
2008-01-17T00:00:00Z